Stevanato Group (NYSE:STVN) Hits New 1-Year High – Here’s Why

Shares of Stevanato Group S.p.A. (NYSE:STVN) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as €25.75 ($28.93) and last traded at €25.40 ($28.54), with a volume of 28624 shares traded. The stock had previously closed at €24.78 ($27.84).

Analyst Ratings Changes

Several equities analysts have recently commented on the company. William Blair reaffirmed an “outperform” rating on shares of Stevanato Group in a research report on Friday, March 7th. UBS Group reduced their price target on Stevanato Group from $24.00 to $23.50 and set a “neutral” rating for the company in a research note on Friday, March 7th. Finally, Stephens upgraded Stevanato Group to a “strong-buy” rating in a research report on Monday, April 21st. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of €25.70 ($28.88).

Stevanato Group Trading Down 1.7%

The firm has a market capitalization of $7.37 billion, a P/E ratio of 51.81, a PEG ratio of 7.18 and a beta of 0.51. The company has a quick ratio of 1.21, a current ratio of 1.81 and a debt-to-equity ratio of 0.22. The firm has a 50 day moving average of €21.50 and a 200-day moving average of €21.23.

Stevanato Group (NYSE:STVN) last announced its quarterly earnings data on Thursday, March 6th. The company reported €0.20 ($0.22) EPS for the quarter, meeting the consensus estimate of €0.20 ($0.22). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The business had revenue of €352.68 million during the quarter, compared to the consensus estimate of €346.26 million. On average, equities research analysts predict that Stevanato Group S.p.A. will post 0.5 earnings per share for the current fiscal year.

Stevanato Group Increases Dividend

The company also recently announced an annual dividend, which will be paid on Thursday, July 17th. Stockholders of record on Thursday, June 5th will be paid a $0.0613 dividend. The ex-dividend date of this dividend is Thursday, June 5th. This is an increase from Stevanato Group’s previous annual dividend of $0.05. This represents a dividend yield of 0.3%. Stevanato Group’s dividend payout ratio (DPR) is currently 11.76%.

Hedge Funds Weigh In On Stevanato Group

A number of institutional investors have recently modified their holdings of the company. Hancock Whitney Corp increased its stake in Stevanato Group by 4.8% during the 1st quarter. Hancock Whitney Corp now owns 11,482 shares of the company’s stock valued at $234,000 after purchasing an additional 528 shares in the last quarter. Van Berkom & Associates Inc. grew its holdings in shares of Stevanato Group by 33.3% during the first quarter. Van Berkom & Associates Inc. now owns 2,400 shares of the company’s stock valued at $49,000 after buying an additional 600 shares during the last quarter. Oppenheimer Asset Management Inc. increased its position in shares of Stevanato Group by 7.8% during the first quarter. Oppenheimer Asset Management Inc. now owns 13,878 shares of the company’s stock worth $283,000 after acquiring an additional 1,004 shares in the last quarter. First Bank & Trust raised its holdings in shares of Stevanato Group by 7.3% in the 4th quarter. First Bank & Trust now owns 15,145 shares of the company’s stock worth $330,000 after acquiring an additional 1,036 shares during the last quarter. Finally, Truist Financial Corp lifted its position in Stevanato Group by 4.2% in the 4th quarter. Truist Financial Corp now owns 26,900 shares of the company’s stock valued at $586,000 after acquiring an additional 1,073 shares in the last quarter.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.